Chd8 haploinsufficiency impairs early brain development and protein homeostasis later in life / Jessica A. JIMÉNEZ in Molecular Autism, 11 (2020)  

Public ISBD [article]  inMolecular Autism > 11 (2020) . - 74 p. Titre : Chd8 haploinsufficiency impairs early brain development and protein homeostasis later in life Type de document : texte imprimé Auteurs : Jessica A. JIMÉNEZ, Auteur ; Travis S. PTACEK, Auteur ; Alex H. TUTTLE, Auteur ; Ralf S. SCHMID, Auteur ; Sheryl S. MOY, Auteur ; Jeremy M. SIMON, Auteur ; Mark J. ZYLKA, Auteur Article en page(s) : 74 p. Langues : Anglais (eng) Mots-clés : Autism spectrum disorder  Brain overgrowth  Chd8  Endoplasmic reticulum stress  Macrocephaly  Unfolded protein response Index. décimale : PER Périodiques Résumé : BACKGROUND: Chromodomain helicase DNA-binding protein 8 (Chd8) is a high-confidence risk gene for autism spectrum disorder (ASD). However, how Chd8 haploinsufficiency impairs gene expression in the brain and impacts behavior at different stages of life is unknown. METHODS: We generated a mutant mouse line with an ASD-linked loss-of-function mutation in Chd8 (V986*; stop codon mutation). We examined the behavior of Chd8 mutant mice along with transcriptional changes in the cerebral cortex as a function of age, with a focus on one embryonic (E14.5) and three postnatal ages (1, 6, and 12 months). RESULTS: Chd8(V986*/+) mutant mice displayed macrocephaly, reduced rearing responses and reduced center time in the open field, and enhanced social novelty preference. Behavioral phenotypes were more evident in Chd8(V986*/+) mutant mice at 1 year of age. Pup survival was reduced in wild-type x Chd8(V986*/+) crosses when the mutant parent was female. Transcriptomic analyses indicated that pathways associated with synaptic and neuronal projections and sodium channel activity were reduced in the cortex of embryonic Chd8(V986*/+) mice and then equalized relative to wild-type mice in the postnatal period. At 12 months of age, expression of genes associated with endoplasmic reticulum (ER) stress, chaperone-mediated protein folding, and the unfolded protein response (UPR) were reduced in Chd8(V986*/+) mice, whereas genes associated with the c-MET signaling pathway were increased in expression. LIMITATIONS: It is unclear whether the transcriptional changes observed with age in Chd8(V986*/+) mice reflect a direct effect of CHD8-regulated gene expression, or if CHD8 indirectly affects the expression of UPR/ER stress genes in adult mice as a consequence of neurodevelopmental abnormalities. CONCLUSIONS: Collectively, these data suggest that UPR/ER stress pathways are reduced in the cerebral cortex of aged Chd8(V986*/+) mice. Our study uncovers neurodevelopmental and age-related phenotypes in Chd8(V986*/+) mice and highlights the importance of controlling for age when studying Chd8 haploinsufficient mice. En ligne : http://dx.doi.org/10.1186/s13229-020-00369-8 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=433 [article] Chd8 haploinsufficiency impairs early brain development and protein homeostasis later in life [texte imprimé] / Jessica A. JIMÉNEZ, Auteur ; Travis S. PTACEK, Auteur ; Alex H. TUTTLE, Auteur ; Ralf S. SCHMID, Auteur ; Sheryl S. MOY, Auteur ; Jeremy M. SIMON, Auteur ; Mark J. ZYLKA, Auteur . - 74 p. Langues : Anglais (eng) in Molecular Autism > 11 (2020) . - 74 p. Mots-clés : Autism spectrum disorder  Brain overgrowth  Chd8  Endoplasmic reticulum stress  Macrocephaly  Unfolded protein response Index. décimale : PER Périodiques Résumé : BACKGROUND: Chromodomain helicase DNA-binding protein 8 (Chd8) is a high-confidence risk gene for autism spectrum disorder (ASD). However, how Chd8 haploinsufficiency impairs gene expression in the brain and impacts behavior at different stages of life is unknown. METHODS: We generated a mutant mouse line with an ASD-linked loss-of-function mutation in Chd8 (V986*; stop codon mutation). We examined the behavior of Chd8 mutant mice along with transcriptional changes in the cerebral cortex as a function of age, with a focus on one embryonic (E14.5) and three postnatal ages (1, 6, and 12 months). RESULTS: Chd8(V986*/+) mutant mice displayed macrocephaly, reduced rearing responses and reduced center time in the open field, and enhanced social novelty preference. Behavioral phenotypes were more evident in Chd8(V986*/+) mutant mice at 1 year of age. Pup survival was reduced in wild-type x Chd8(V986*/+) crosses when the mutant parent was female. Transcriptomic analyses indicated that pathways associated with synaptic and neuronal projections and sodium channel activity were reduced in the cortex of embryonic Chd8(V986*/+) mice and then equalized relative to wild-type mice in the postnatal period. At 12 months of age, expression of genes associated with endoplasmic reticulum (ER) stress, chaperone-mediated protein folding, and the unfolded protein response (UPR) were reduced in Chd8(V986*/+) mice, whereas genes associated with the c-MET signaling pathway were increased in expression. LIMITATIONS: It is unclear whether the transcriptional changes observed with age in Chd8(V986*/+) mice reflect a direct effect of CHD8-regulated gene expression, or if CHD8 indirectly affects the expression of UPR/ER stress genes in adult mice as a consequence of neurodevelopmental abnormalities. CONCLUSIONS: Collectively, these data suggest that UPR/ER stress pathways are reduced in the cerebral cortex of aged Chd8(V986*/+) mice. Our study uncovers neurodevelopmental and age-related phenotypes in Chd8(V986*/+) mice and highlights the importance of controlling for age when studying Chd8 haploinsufficient mice. En ligne : http://dx.doi.org/10.1186/s13229-020-00369-8 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=433

Controlling litter effects to enhance rigor and reproducibility with rodent models of neurodevelopmental disorders / Jessica A. JIMÉNEZ in Journal of Neurodevelopmental Disorders, 13 (2021)  

Public ISBD [article]  inJournal of Neurodevelopmental Disorders > 13 (2021) Titre : Controlling litter effects to enhance rigor and reproducibility with rodent models of neurodevelopmental disorders Type de document : texte imprimé Auteurs : Jessica A. JIMÉNEZ, Auteur ; Mark J. ZYLKA, Auteur Langues : Anglais (eng) Mots-clés : Animals  Female  Haploinsufficiency  Mice  Neurodevelopmental Disorders/chemically induced/genetics  Phenotype  Pregnancy  Reproducibility of Results  Animal models  Litter effect  Neurodevelopmental disorders  Rigor and reproducibility Index. décimale : PER Périodiques Résumé : Research with rodents is crucial for expanding our understanding of genetic and environmental risk factors for neurodevelopmental disorders (NDD). However, there is growing concern about the number of animal studies that are difficult to replicate, potentially undermining the validity of results. These concerns have prompted funding agencies and academic journals to implement more rigorous standards in an effort to increase reproducibility in research. However, these standards fail to address a major source of variability in rodent research brought on by the "litter effect," the fact that rodents from the same litter are phenotypically more similar to one other than rodents from different litters of the same strain. We show that the litter effect accounts for 30-60% of the variability associated with commonly studied phenotypes, including brain, placenta, and body weight. Moreover, we show how failure to control for litter-to-litter variation can mask a phenotype in Chd8(V986*/+) mice that model haploinsufficiency of CHD8, a high-confidence autism gene. Thus, if not properly controlled, the litter effect has the potential to negatively influence rigor and reproducibility of NDD research. While efforts have been made to educate scientists on the importance of controlling for litter effects in previous publications, our analysis of the recent literature (2015-2020) shows that the vast majority of NDD studies focused on genetic risks, including mutant mouse studies, and environmental risks, such as air pollution and valproic acid exposure, do not correct for litter effects or report information on the number of litters used. We outline best practices to help scientists minimize the impact of litter-to-litter variability and to enhance rigor and reproducibility in future NDD studies using rodent models. En ligne : https://dx.doi.org/10.1186/s11689-020-09353-y Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=573 [article] Controlling litter effects to enhance rigor and reproducibility with rodent models of neurodevelopmental disorders [texte imprimé] / Jessica A. JIMÉNEZ, Auteur ; Mark J. ZYLKA, Auteur. Langues : Anglais (eng) in Journal of Neurodevelopmental Disorders > 13 (2021) Mots-clés : Animals  Female  Haploinsufficiency  Mice  Neurodevelopmental Disorders/chemically induced/genetics  Phenotype  Pregnancy  Reproducibility of Results  Animal models  Litter effect  Neurodevelopmental disorders  Rigor and reproducibility Index. décimale : PER Périodiques Résumé : Research with rodents is crucial for expanding our understanding of genetic and environmental risk factors for neurodevelopmental disorders (NDD). However, there is growing concern about the number of animal studies that are difficult to replicate, potentially undermining the validity of results. These concerns have prompted funding agencies and academic journals to implement more rigorous standards in an effort to increase reproducibility in research. However, these standards fail to address a major source of variability in rodent research brought on by the "litter effect," the fact that rodents from the same litter are phenotypically more similar to one other than rodents from different litters of the same strain. We show that the litter effect accounts for 30-60% of the variability associated with commonly studied phenotypes, including brain, placenta, and body weight. Moreover, we show how failure to control for litter-to-litter variation can mask a phenotype in Chd8(V986*/+) mice that model haploinsufficiency of CHD8, a high-confidence autism gene. Thus, if not properly controlled, the litter effect has the potential to negatively influence rigor and reproducibility of NDD research. While efforts have been made to educate scientists on the importance of controlling for litter effects in previous publications, our analysis of the recent literature (2015-2020) shows that the vast majority of NDD studies focused on genetic risks, including mutant mouse studies, and environmental risks, such as air pollution and valproic acid exposure, do not correct for litter effects or report information on the number of litters used. We outline best practices to help scientists minimize the impact of litter-to-litter variability and to enhance rigor and reproducibility in future NDD studies using rodent models. En ligne : https://dx.doi.org/10.1186/s11689-020-09353-y Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=573

Correction to: Chd8 haploinsufficiency impairs early brain development and protein homeostasis later in life / Jessica A. JIMÉNEZ in Molecular Autism, 12 (2021)  

Public ISBD [article]  inMolecular Autism > 12 (2021) . - 33 p. Titre : Correction to: Chd8 haploinsufficiency impairs early brain development and protein homeostasis later in life Type de document : texte imprimé Auteurs : Jessica A. JIMÉNEZ, Auteur ; Travis S. PTACEK, Auteur ; Alex H. TUTTLE, Auteur ; Ralf S. SCHMID, Auteur ; Sheryl S. MOY, Auteur ; Jeremy M. SIMON, Auteur ; Mark J. ZYLKA, Auteur Article en page(s) : 33 p. Langues : Anglais (eng) Index. décimale : PER Périodiques En ligne : http://dx.doi.org/10.1186/s13229-021-00438-6 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=459 [article] Correction to: Chd8 haploinsufficiency impairs early brain development and protein homeostasis later in life [texte imprimé] / Jessica A. JIMÉNEZ, Auteur ; Travis S. PTACEK, Auteur ; Alex H. TUTTLE, Auteur ; Ralf S. SCHMID, Auteur ; Sheryl S. MOY, Auteur ; Jeremy M. SIMON, Auteur ; Mark J. ZYLKA, Auteur . - 33 p. Langues : Anglais (eng) in Molecular Autism > 12 (2021) . - 33 p. Index. décimale : PER Périodiques En ligne : http://dx.doi.org/10.1186/s13229-021-00438-6 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=459

Prenatal treatment path for angelman syndrome and other neurodevelopmental disorders / Mark J. ZYLKA in Autism Research, 13-1 (January 2020)  

Public ISBD [article]  inAutism Research > 13-1 (January 2020) . - p.11-17 Titre : Prenatal treatment path for angelman syndrome and other neurodevelopmental disorders Type de document : texte imprimé Auteurs : Mark J. ZYLKA, Auteur Article en page(s) : p.11-17 Langues : Anglais (eng) Mots-clés : autism spectrum disorder  birth weight  case-control study  epidemiology  risk markers Index. décimale : PER Périodiques Résumé : Angelman syndrome (AS) is a rare neurodevelopmental disorder caused by mutation or deletion of the maternally inherited UBE3A allele. These pathogenic mutations lead to loss of maternal UBE3A expression in neurons. Antisense oligonucleotides and gene therapies are in development, which activate the intact but epigenetically silenced paternal UBE3A allele. Preclinical studies indicate that treating during the prenatal period could greatly reduce the severity of symptoms or prevent AS from developing. Genetic tests can detect the chromosome 15q11-q13 deletion that is the most common cause of AS. New, highly sensitive noninvasive prenatal tests that take advantage of single-cell genome sequencing technologies are expected to enter the clinic in the coming years and make early genetic diagnosis of AS more common. Efforts are needed to identify fetuses and newborns with maternal 15q11-q13 deletions and to phenotype these babies relative to neurotypical controls. Clinical and parent observations suggest AS symptoms are detectable in infants, including reports of problems with feeding and motor function. Quantitative phenotypes in the 0- to 1-year age range will permit a more rapid assessment of efficacy when future treatments are administered prenatally or shortly after birth. Although prenatal therapies are currently not available for AS, prenatal testing combined with prenatal treatment has the potential to revolutionize how clinicians detect and treat babies before they are symptomatic. This pioneering prenatal treatment path for AS will lay the foundation for treating other syndromic neurodevelopmental disorders. Autism Res 2020, 13: 11-17. (c) 2019 International Society for Autism Research, Wiley Periodicals, Inc. LAY SUMMARY: Prenatal treatment could benefit expectant parents whose babies test positive for the chromosome microdeletion that causes Angelman syndrome (AS). Prenatal treatment is predicted to have better outcomes than treating after symptoms develop and may even prevent AS altogether. This approach could generally be applied to the treatment of other syndromic neurodevelopmental disorders. En ligne : http://dx.doi.org/10.1002/aur.2203 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=415 [article] Prenatal treatment path for angelman syndrome and other neurodevelopmental disorders [texte imprimé] / Mark J. ZYLKA, Auteur . - p.11-17. Langues : Anglais (eng) in Autism Research > 13-1 (January 2020) . - p.11-17 Mots-clés : autism spectrum disorder  birth weight  case-control study  epidemiology  risk markers Index. décimale : PER Périodiques Résumé : Angelman syndrome (AS) is a rare neurodevelopmental disorder caused by mutation or deletion of the maternally inherited UBE3A allele. These pathogenic mutations lead to loss of maternal UBE3A expression in neurons. Antisense oligonucleotides and gene therapies are in development, which activate the intact but epigenetically silenced paternal UBE3A allele. Preclinical studies indicate that treating during the prenatal period could greatly reduce the severity of symptoms or prevent AS from developing. Genetic tests can detect the chromosome 15q11-q13 deletion that is the most common cause of AS. New, highly sensitive noninvasive prenatal tests that take advantage of single-cell genome sequencing technologies are expected to enter the clinic in the coming years and make early genetic diagnosis of AS more common. Efforts are needed to identify fetuses and newborns with maternal 15q11-q13 deletions and to phenotype these babies relative to neurotypical controls. Clinical and parent observations suggest AS symptoms are detectable in infants, including reports of problems with feeding and motor function. Quantitative phenotypes in the 0- to 1-year age range will permit a more rapid assessment of efficacy when future treatments are administered prenatally or shortly after birth. Although prenatal therapies are currently not available for AS, prenatal testing combined with prenatal treatment has the potential to revolutionize how clinicians detect and treat babies before they are symptomatic. This pioneering prenatal treatment path for AS will lay the foundation for treating other syndromic neurodevelopmental disorders. Autism Res 2020, 13: 11-17. (c) 2019 International Society for Autism Research, Wiley Periodicals, Inc. LAY SUMMARY: Prenatal treatment could benefit expectant parents whose babies test positive for the chromosome microdeletion that causes Angelman syndrome (AS). Prenatal treatment is predicted to have better outcomes than treating after symptoms develop and may even prevent AS altogether. This approach could generally be applied to the treatment of other syndromic neurodevelopmental disorders. En ligne : http://dx.doi.org/10.1002/aur.2203 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=415

---

1 (1 - 4 / 4) Par page : 25 50 100 200